The United States has one of the highest incarceration rates in the world, with nearly 2 million people in the criminal justice system facing potential barriers to accessing timely, quality care. Now, Yale researchers are finding that individuals with a history of incarceration are more likely to be diagnosed with cancer and are less likely to survive the disease.
- March 06, 2023
A team of Yale scientists seeks to determine which treatment sequences produce the best results for people with advanced cancer while examining the cost of these treatments.
- March 06, 2023Source: The Washington Post
Almost eight years ago, a dire health threat to the former president put the spotlight on a pathbreaking immune therapy
- February 20, 2023
Michael Leapman, MD, MHS, and his research team produce never-before figures focused on the prostate biopsy and/or MRI. Learn what they're asking more physicians to consider when it comes to patient care and environmental impact.
- February 15, 2023Source: YaleNews
Black patients are less likely than other groups to receive early uterine cancer diagnoses. A new Yale study finds they experience delays in diagnostic tests.
- January 26, 2023
Although widespread use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer has led to meaningful improvements in survival in younger patients, older patients have not experienced similar survival benefits, new research from Yale Cancer Center shows. The study was published in JAMA Oncology.
- January 26, 2023Source: Healio
Despite significantly extending survival for younger adults with advanced non-small cell lung cancer, immune checkpoint inhibitors have conferred only modest OS gains over time among patients aged older than 75 years, study results showed.
- January 04, 2023Source: Healio
Incarcerated Adults at Higher Risk for Cancer Mortality
- December 15, 2022
Yale-led Study Seeks to Understand How PET Imaging is Touching the Lives of Patients with Prostate Cancer
Although PET imaging is more accurate at identifying cancer, it is still not known how that accuracy will affect treatments, and whether localization will improve outcomes for patients. To help answer these questions, Yale Urology Associate Professor Michael Leapman, MD, MHS, is leading a collaborative study.
- November 29, 2022
New cancer treatments can look promising in clinical trials. But they do no good if patients don’t receive them. That innovative, purportedly miraculous medication? Are clinicians prescribing it? Can patients afford it? Does it significantly improve patients’ lives?